Spotlight on Cancer Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of São Paulo, is a state institution that will care for cancer patients from São Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of São Paulo.

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of So Paulo, is a state institution that will care for cancer patients from So Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of So Paulo.

The new cancer center is named after Octavio Frias de Oliveira, who built a media empire in Brazil and was publisher of Folha de So Paulo, Brazil’s largest newpaper. Mr. Frias died last year at age 94.

Managed by medical school


With 580 beds, the new hospital will be managed by The Medical School of the University of So Paulo, the premier medical school in Brazil.

The Institute will focus on medical care, education, and research. The objective is to position the Institute as one of the main research centers in the world. 

When operating at full capacity, it is estimated that the Institute will deliver care to approximately 16,000 new patients every year. It occupies a 28-floor building, with 540,000 square feet dedicated to cancer care and research.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content